Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
Manuel Dómine Gómez, Tibor Csőszi, Rajesh K. Malik, Krasimir Nikolov, Iveta Kudaba, Davorin Radosavljevic, Jana Jaal, Janet K. Horton, Jie Xiao, Janakiraman Subramanian
Publikováno v:
International Journal of Cancer
Chemotherapy-induced myelosuppression is an acute, dose-limiting toxicity of chemotherapy regimens used in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemother
Autor:
Dooreh Kim, Jee Ye Kim, Byeong Woo Park, Seung Il Kim, Joon Jeong, Soong June Bae, Janghee Lee, Chihwan Cha, Hyung Seok Park, Soeun Park, Seho Park, Sung Gwe Ahn
Publikováno v:
International Journal of Cancer
Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into neoadjuvant systemic therapy (NST) led to higher response in patients with HER2‐positive breast cancer. However, axillary response to treatment regimens, including sin
Autor:
Akihito Tsuji, Satoshi Kaihara, Michio Inukai, Takanori Watanabe, Toshihiko Matsumoto, Masahito Kotaka, Hiroki Hashida, Yasuhiro Miyake, Hiroaki Tanioka, Hisateru Yasui, Masato Matsuura, Shinichi Yoshioka, Yoshihiro Okita, Takeshi Kotake, Takahisa Kyogoku, Takeshi Kato, Hironaga Satake
Publikováno v:
The Oncologist
Lessons Learned Background The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3-month adjuvant treatment with capecita
Autor:
Shuvayu S Sen, Monika Raut, Dominique Lejeune, Guillaume Germain, François Laliberté, Philippe Armand, Xiaoqin Yang, Mei Sheng Duh, Kaushal Desai
Publikováno v:
The Oncologist
Background Diffuse large B‐cell lymphoma (DLBCL) represents the most common subtype of non‐Hodgkin lymphoma in the U.S., but current real‐world data are limited. This study was conducted to describe real‐world characteristics, treatment patte
Autor:
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Thao Dang, Sara Sadowski, Debra A. Kush, Yu Zhou, Ben Li, Tony Mok
Publikováno v:
International Journal of Cancer
In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/meta
Publikováno v:
The Oncologist
Trial Information Click here to access other published clinical trials. Lessons Learned Studies targeting cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin (C-CAG) regimen in relapsed and refra
Autor:
Christina Cox, Michele Spina, Samantha Ferrari, Luigi Rigacci, Francesco Merli, Francesco Angrilli, Silvia Bolis, Antonino Mulè, Stefano Luminari, Maria Luigia Vigliotti, Ombretta Annibali, Pier Luigi Zinzani, Samantha Pozzi, Guido Gini, Elisabetta Bonifacio, Francesca Pregnolato, Serena Broggi, S. Kovalchuk, Scalzulli Rp, Angela Maria Mamusa, Armando Santoro, Gloria Margiotta-Casaluci, L. Flenghi, Umberto Vitolo, Fondazione Italiana Linfomi
Publikováno v:
Hematological Oncology
Doxorubicin is the most effective single agent in the treatment of non‐Hodgkin's lymphoma (NHL). Its use is limited because of the cardiac toxicity primarily in elderly patients (pts) and in pts with history of cardiac disease. Liposomal doxorubici
Publikováno v:
International Journal of Cancer
There is increasing interest regarding potential protective effects of low‐dose aspirin against various gastrointestinal cancers. We aimed to quantify the association between use of low‐dose aspirin and risk of gastric/oesophageal cancer using a
Autor:
Erik Vegt, Sushil K Badrising, Olaf Loosveld, Paul Hamberg, Andries M. Bergman, Ad Oostdijk, Nils Wagenaar, Jules L.L.M. Coenen, Marnix G.E.H. Lam, Vincent van der Noort, Hanneke J. M. Zuetenhorst, Aart Beeker, Filiz Celik, John B. A. G. Haanen, Wilbert Zwart, Rebecca D Louhanepessy
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 147, 4, pp. 1143-51
International Journal of Cancer, 147, 1143-51
International Journal of Cancer, 147, 4, pp. 1143-51
International Journal of Cancer, 147, 1143-51
The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium‐223 dichloride (Ra‐223) over placebo. Here we report clinical outcomes of Ra‐223 tr
Publikováno v:
The Oncologist
Background Erdheim‐Chester disease (ECD) is a rare non‐Langerhans cell histiocytosis. The BRAF inhibitor vemurafenib is approved by the U.S. Food and Drug Administration (FDA) for patients with ECD harboring a BRAF V600E mutation. Successful trea